摘要
目的探讨肝动脉化疗栓塞术(TACE)术后肝衰竭的发生与髓源性免疫抑制细胞(MDSC)表达的关系。方法选取2011年5月~2015年1月住院的237例乙肝病毒(HBV)相关原发性肝癌(PLC)患者作为研究对象,按照是否发生肝衰竭分为肝衰竭组(105例)与非肝衰竭组(132例),分析MDSC表达TACE术后肝衰竭的差异。按照肝衰竭程度分为肝衰竭轻度组(47例)、中度组(31例)、重度组(27例),按照肝衰竭预后分为死亡组(10例)与好转组(95例),比较各组MDSC表达差异。结果 PLC患者肝衰竭组的MDSC-m表型明显高于非肝衰竭组,差异有统计学意义(P=0.0405)。肝衰竭重度组的MDSC-m明显高于轻度组,差异有统计学意义(P<0.001);肝衰竭死亡组的MDSC-m水平明显高于好转组,差异有统计学意义(P<0.01)。结论肝动脉化疗栓塞术后肝衰竭发生、预后与MDSC高表达密切相关。
Objective To investigate the relationship between the occurrence of hepatic failure after transcatheter arterial chemoembolization(TACE)and the expression of myeloid-derived suppressor cell(MDSC).Methods Altogether 237 patients with HBV-related primary liver cancer(PLC)who were hospitalized in our hospital from May 2011 to January 2015 were selected as the subject of this research,according to the the occurrence of liver failure,all patients were divided into 105 cases in liver failure group and 132 cases in non-liver failure group.The difference of MDSC expressions after TACE was analyzed.According to the degree of liver failure,all the patients were divided into mild liver failure group(47 cases),moderate group(31 cases),severe group(27 cases),according to the prognosis of liver failure,all the patients were divided into death group(10 cases)and improvement group(95 cases).The difference of MDSC expressions in each group was compared.Results The MDSC-m phenotype of the PLC patients in liver failure group was significantly higher than that in the non-liver failure group,with significant difference(P=0.0405).MDSC-m of severe liver failure group was significantly higher than that of mild group,with significant difference between the two groups(P<0.001).MDSC-m level of the liver failure death group was significantly higher than that of improvement group,with significant difference between the two groups(P<0.01).Conclusion The occurrence and prognosis of hepatic failure after TACE is closely related to the high expression of MDSC.
作者
张巍
邵明亮
刘文宗
张海丛
闫会敏
郑欢伟
ZHANG Wei;SHAO Ming-liang;LIU Wen-zong;ZHANG Hai-cong;YAN Hui-min;ZHENG Huan-wei(Research Center,the Fifth Hospital of Shijiazhuang,Hebei Province,Shijiazhuang 050021,China)
出处
《中国当代医药》
2018年第10期9-12,共4页
China Modern Medicine
关键词
肝癌
肝动脉化疗栓塞术
髓源性免疫抑制细胞
Liver cancer
Transcatheter arterial chemoembolization
Myeloid-derived suppressor cell
